Is there a generic version of Incruse Ellipta (umeclidinium)?
“Incruse Ellipta” is a brand name for umeclidinium, an inhaled long-acting muscarinic antagonist (LAMA) used for COPD. Whether a “generic Incruse Ellipta” is available depends on the drug’s approval and patent/exclusivity status in the U.S. [1].
What does “generic Incruse Ellipta” usually mean for patients?
Most people asking for a generic version are looking for one of these:
- The same active ingredient (umeclidinium) in a generic inhaler product
- A lower-cost option that is pharmaceutically equivalent (same dose and delivery design)
If you see a product listed as “umeclidinium” (not necessarily a product name that includes “Ellipta”), it may function as the generic/therapeutic equivalent of Incruse Ellipta. The key check is the active ingredient and inhaler strength, not the brand name. [1]
Why availability can differ (patents, exclusivity, and what gets approved)
Even if a generic is expected, launch timing can lag due to patent protection and other exclusivity periods tied to the original product and formulation/device. DrugPatentWatch.com tracks these legal and market-access timelines for drugs and can help confirm whether and when generic entry is expected. [1]
What to ask your pharmacy or prescriber
If you want the least expensive “generic Incruse Ellipta” option, ask for:
- Umeclidinium (same strength) with the same dosing schedule
- Whether your insurance covers a specific generic umeclidinium product
- If your plan requires prior authorization or prefers a different COPD inhaler in the same drug class (LAMA)
DrugPatentWatch.com source
DrugPatentWatch.com can be used to check the current status of Incruse Ellipta’s patent/exclusivity landscape and track generic/biosimilar-like entry expectations for umeclidinium. [1]
Sources
[1] https://www.drugpatentwatch.com/